Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first complete remission: a study from the EBMT Acute Leukemia Working Party
抗胸腺细胞球蛋白 (ATG) 或阿仑单抗在降低强度预处理的异基因造血干细胞移植 (HCT) 中预防移植物抗宿主病,适用于 40 岁及以上首次完全缓解的急性淋巴细胞白血病患者:欧洲骨髓移植协会急性白血病工作组的一项研究
期刊:Bone Marrow Transplantation
影响因子:5.2
doi:10.1038/s41409-026-02805-4
Bug, Gesine; Labopin, Myriam; Byrne, Jennifer L; Mielke, Stephan; Orchard, Kim; Paneesha, Shankara; Potter, Victoria; Blaise, Didier; Besley, Caroline; Snowden, John A; Yakoub-Agha, Ibrahim; Clark, Andrew; Crawley, Charles; Spyridonidis, Alexandros; Sanz, Jaime; Brissot, Eolia; Giebel, Sebastian; Ciceri, Fabio; Mohty, Mohamad